The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis
Abstract
OBJECTIVES: To improve the bioavailability of antitubercular drugs (ATDs) as well as to assess the feasibility of administering ATDs via the respiratory route, this study reports the formulation of three frontline ATDs, i.e. rifampicin, isoniazid and pyrazinamide encapsulated in poly (DL-lactide-co-glycolide) nanoparticles suitable for nebulization. METHODS: Drug-loaded nanoparticles were prepared by the multiple emulsion technique, vacuum-dried and nebulized to guinea pigs. The formulation was evaluated with respect to the pharmacokinetics of each drug and its chemotherapeutic potential in Mycobacterium tuberculosis infected guinea pigs. RESULTS: The aerosolized particles exhibited a mass median aerodynamic diameter of 1.88 +/- 0.11 microm, favourable for bronchoalveolar lung delivery. A single nebulization to guinea pigs resulted in sustained therapeutic drug levels in the plasma for 6-8 days and in the lungs for up to 11 days. The elimination half-life and mean residence time of the drugs were significantly prolonged compared to when the parent drugs were administered orally, resulting in an enhanced relative bioavailability (compared to oral administration) for encapsulated drugs (12.7-, 32.8- and 14.7-fold for rifampicin, isoniazid and pyrazinamide, respectively). The absolute bioavailability [compared to intravenous (i.v.) administration] was also increased by 6.5-, 19.1- and 13.4-fold for rifampicin, isoniazid and pyrazinamide, respectively. On nebulization of nanoparticles containing drugs to M. tuberculosis infected guinea pigs at every 10th day, no tubercle bacilli could be detected in the lung after five doses of treatment whereas 46 daily doses of orally administered drug were required to obtain an equivalent therapeutic benefit. CONCLUSIONS: Nebulization of nanoparticles-based ATDs forms a sound basis for improving drug bioavailability and reducing the dosing frequency for better management of pulmonary tuberculosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dhuley, J. N. (1999) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.1999.tb01347.x · Cited by 4
RetractedBiodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(97)00048-3 · Cited by 2,617
Sahoo, S. K., Panyam, J., Prabha, S., & Labhasetwar, V. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00127-x · Cited by 990
Biodegradation and biocompatibility of PLA and PLGA microspheres
Anderson, J. M., & Shive, M. S. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.004 · Cited by 814
Infectious Diseases: Considerations for the 21st Century
Fauci, A. S. (2001) · Clinical Infectious Diseases · doi:10.1086/319235 · Cited by 443
Production and Characterization of a Budesonide Nanosuspension for Pulmonary Administration
Jacobs, C., & Müller, R. H. (2002) · Pharmaceutical Research · doi:10.1023/a:1014276917363 · Cited by 439
Sharma, R., Saxena, D., Dwivedi, A. K., & Misra, A. (2001) · Pharmaceutical Research · doi:10.1023/a:1012296604685 · Cited by 201
Dailey, L. A., Schmehl, T., Gessler, T., Wittmar, M., Grimminger, F., Seeger, W., & Kissel, T. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00370-x · Cited by 180
Biodegradable monodispersed nanoparticles prepared by pressure homogenization-emulsification
Lamprecht, A., Ubrich, N., Hombreiro Pérez, M., Lehr, C.-M., Hoffman, M., & Maincent, P. (1999) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(99)00107-6 · Cited by 169
Deol, P., & Khuller, G. K. (1997) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(96)00088-8 · Cited by 160
Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration
Grabnar, P. A., Kristl, J., Kristl, A., & Vrečer, F. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00076-5 · Cited by 157
Airways delivery of rifampicin microparticles for the treatment of tuberculosis
Suarez, S. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/48.3.431 · Cited by 155
Horisawa, E., Hirota, T., Kawazoe, S., Yamada, J., Yamamoto, H., Takeuchi, H., & Kawashimà, Y. (2002) · Pharmaceutical Research · doi:10.1023/a:1015123024113 · Cited by 138
Determination of poly(vinyl alcohol) via its complex with boric acid and iodine
Joshi, D., Lan-Chun-Fung, Y. L., & Pritchard, J. G. (1979) · Analytica Chimica Acta · doi:10.1016/s0003-2670(01)83825-3 · Cited by 97
Saito, H., & Tomioka, H. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.4.429 · Cited by 50
Fluorometric determination of isonicotinic acid hydrazide in serum.
Scott, E. M., & Wright, R. C. (1967) · PubMed · Cited by 48
Dutt, M., & Khuller, G. K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.1.363-366.2001 · Cited by 47
Quenelle, D. C., Winchester, G. A., Staas, J. K., Barrow, E. L. W., & Barrow, W. W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1637-1644.2001 · Cited by 44
ul-Ain, Q., Sharma, S., & Khuller, G. K. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.9.3005-3007.2003 · Cited by 40
Atovaquone and rifabutine-loaded nanocapsules: formulation studies
Dalençon, F., Amjaud, Y., Lafforgue, C., Derouin, F., & Fessi, H. (1997) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00076-8 · Cited by 37
Lopes, E., Pohlmann, A. R., Bassani, V. L., & Guterres, S. S. (2000) · PubMed · Cited by 35
Methods for the estimation of pyrazinamide and pyrazinoic acid in body fluids.
Gurumurthy, P., Nair, N., & Sarma, G. R. (1980) · PubMed · Cited by 18
Cited by
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201403036 · Cited by 2,164
Drug delivery systems: An updated review
Tiwari, G., Tiwari, R., Bannerjee, S., Bhati, L., Pandey, S., Pandey, P., & Sriwastawa, B. (2012) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.96920 · Cited by 1,671
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-613pp · Cited by 745
Nanoparticles for drug delivery to the lungs
Sung, J. C., Pulliam, B. L., & Edwards, D. A. (2007) · Trends in Biotechnology · doi:10.1016/j.tibtech.2007.09.005 · Cited by 643
Nanomedicine in pulmonary delivery
Mansour, H., Haemosu, & Wu, X. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s4937 · Cited by 485
Metadata
- Authors
- Pandey, R.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-11-12
- Volume
- 52
- Issue
- 6
- Pages
- 981-986
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2129055298
- Cited by
- 388
- References
- 22
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.